SubHero Banner

Lartruvo® (olaratumab) – Safety communication

January 24, 2019 - The FDA released a statement recommending that patients who are currently receiving Lartruvo (olaratumab) should consult with their healthcare provider about whether to remain on treatment. In addition, the FDA recommends that Lartruvo should not be initiated in new patients outside of an investigational study.

Download PDF